Carmen E. Martin

Welwyn Garden City, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.

JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.

Journal: Journal of neurology

Published: January 26, 2024

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.

Journal: Neurology and therapy

Published: July 03, 2023

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).

Journal: Journal of neurology

Published: April 18, 2023

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.

Journal: Neurology and therapy

Published: November 08, 2022

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).

Journal: Journal of neurology

Published: October 26, 2022

Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.

Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.

Journal: European journal of neurology

Published: March 08, 2022

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.

Journal: The Lancet. Neurology

Published: May 10, 2021

Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B.

Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B.

Journal: Journal of pediatric gastroenterology and nutrition

Published: March 15, 2021

Blurring the boundary between homogenous and heterogeneous catalysis using palladium nanoclusters with dynamic surfaces.

Blurring the boundary between homogenous and heterogeneous catalysis using palladium nanoclusters with dynamic surfaces.

Journal: Nature communications

Published: March 19, 2020

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Journal: Respiratory medicine

Published: July 21, 2017

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.

Journal: PloS one

Published: July 31, 2013

Metabolic acidosis: neo-considerations for general surgeons.

Metabolic acidosis: neo-considerations for general surgeons.

Journal: Annals of the Royal College of Surgeons of England

Published: November 08, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026